Austria Infection Control Market - Forecasts from 2020 to 2025
Austria infection control market is projected to grow at a CAGR of 7.21% during the forecast period. The increasing engagement in the tourism sector is poised to drive the Austria infection control market to new heights during the forecast period. Around 66,420 accommodation facilities were registered in 2018 which is an increase of ?1,590? facilities from 64,830 accommodation facilities. Further for the year 2018, there were 149,819,382 overnight stays registered and increased to 153 million overnight stays with 46 million guests in 2019. The tourism intensity of Austria is 14.4 overnight stays per inhabitant without considering private accommodation [Source: STATcube – Statistical Database of STATISTICS AUSTRIA, Bundesanstalt Statistik ?sterreich]. This catapults Austria in fourth place in an EU comparison. Thus, along with the aforesaid aspects that contribute to the burgeoning tourism industry, it paves the way for the proliferation of the food and beverage segment. This translates to the imperative of establishments thus the entire tourism sector as a whole to integrate safe and full proof infection prevention and control measures to prevent any unwanted cross-contamination. Further to prevent any spoilage thus preventing any loss of revenue as well. These developments are expected to propel the growth of Austria Infection Control Market. ?
The healthcare expenditure of the country and other integral aspects pertaining to healthcare are also one of the prime factors that are poised to propel the infection control market in Austria to an unprecedented height during the forecast period. In 2018, public current expenditure on health amounted to €29 725 million or a share of 74.7% of all current health care spending. Taking public gross capital formation into account, public expenditure amounted to €31,156 million. The biggest share of general government expenditure on health (45.8%) in 2018 was spent on inpatient care (incl. inpatient long-term care). The other main spending categories were outpatient care (26.5%), pharmaceutical products, medical durables and non-durables (13.5%) and home-based health care (8.0%). Considering the period 2004 to 2018 public current health expenditure rose from €17 267 million to €29 725 million, which corresponds to an average annual growth rate of 4.0%. On the other hand, private households and private insurance enterprises spent €9 348 million on health care. With a share of 31.3%, the largest expenditure category of private households and private insurance enterprises was outpatient care. Another 28.7% were spent on pharmaceutical products, medical durables, and non-durables, while the third-largest share (28.3%) was allocated to inpatient care. 7.7% was spent on health administration, 2.2% on home-based health care, among others. In 2018, the health expenditure in Austria accounted for €39 791 million or 10.3% of gross domestic product (GDP) and places Austria on rank 10 of top spending countries for health across the OECD. of which €12 032 million (30.2%) were borne by central, state and local governments and another €17 693 million (44.5%) by social health insurance [Source: STATISTIK AUSTRIA, Bundesanstalt Statistik ?sterreich]. Therefore, from nth aforesaid, it is discerned that there the healthcare environment is conducive for the rapid growth of Austria Infection Control Market during the forecast period.
Segmentation
The healthcare expenditure of the country and other integral aspects pertaining to healthcare are also one of the prime factors that are poised to propel the infection control market in Austria to an unprecedented height during the forecast period. In 2018, public current expenditure on health amounted to €29 725 million or a share of 74.7% of all current health care spending. Taking public gross capital formation into account, public expenditure amounted to €31,156 million. The biggest share of general government expenditure on health (45.8%) in 2018 was spent on inpatient care (incl. inpatient long-term care). The other main spending categories were outpatient care (26.5%), pharmaceutical products, medical durables and non-durables (13.5%) and home-based health care (8.0%). Considering the period 2004 to 2018 public current health expenditure rose from €17 267 million to €29 725 million, which corresponds to an average annual growth rate of 4.0%. On the other hand, private households and private insurance enterprises spent €9 348 million on health care. With a share of 31.3%, the largest expenditure category of private households and private insurance enterprises was outpatient care. Another 28.7% were spent on pharmaceutical products, medical durables, and non-durables, while the third-largest share (28.3%) was allocated to inpatient care. 7.7% was spent on health administration, 2.2% on home-based health care, among others. In 2018, the health expenditure in Austria accounted for €39 791 million or 10.3% of gross domestic product (GDP) and places Austria on rank 10 of top spending countries for health across the OECD. of which €12 032 million (30.2%) were borne by central, state and local governments and another €17 693 million (44.5%) by social health insurance [Source: STATISTIK AUSTRIA, Bundesanstalt Statistik ?sterreich]. Therefore, from nth aforesaid, it is discerned that there the healthcare environment is conducive for the rapid growth of Austria Infection Control Market during the forecast period.
Segmentation
- By Product
- Disinfectants
- Sterilization
- Low-Temperature Sterilization
- Heat Sterilization
- Contract Sterilization
- By End User Industry
- Healthcare
- Food and Beverage
- Chemical
1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. AUSTRIA INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. AUSTRIA INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Belimed
8.2. CertoClav Sterilizer GmbH
8.3. MELAG Medizintechnik GmbH & Co. KG
8.4. SMEG
8.5. Steelco S.p.A.
8.6. List is not Exhaustive*
1.1. Market Definition
1.2. Market Segmentation
2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions
3. EXECUTIVE SUMMARY
3.1. Research Highlights
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porters Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. The threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. AUSTRIA INFECTION CONTROL MARKET, BY PRODUCT
5.1. Introduction
5.2. Disinfectants
5.3. Sterilization
5.3.1. Low-Temperature Sterilization
5.3.2. Heat Sterilization
5.3.3. Contract Sterilization
6. AUSTRIA INFECTION CONTROL MARKET, BY END USER INDUSTRY
6.1. Introduction
6.2. Healthcare
6.3. Food and Beverage
6.4. Chemical
7. COMPETITIVE ENVIRONMENT AND ANALYSIS
7.1. Major Players and Strategy Analysis
7.2. Emerging Players and Market Lucrativeness
7.3. Mergers, Acquisitions, Agreements, and Collaborations
7.4. Vendor Competitiveness Matrix
8. COMPANY PROFILES
8.1. Belimed
8.2. CertoClav Sterilizer GmbH
8.3. MELAG Medizintechnik GmbH & Co. KG
8.4. SMEG
8.5. Steelco S.p.A.
8.6. List is not Exhaustive*
